Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: Results of 4-year studies

BJU International

Volumn 96, Issue 4, 2005, Pages 572-577

  Roehrborn, Claus G ^a   Lukkarinen, Olavi ^b   Mark, Stephen ^c   Siami, Paul ^d   Ramsdell, Joe ^e   Zinner, Norman ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF OULU   (Finland)

^c St George's Hospital   (New Zealand)

^d Welborn Baptist Hospital   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Western Clinical Research   (United States)

Author keywords

BPH; Dutasteride; Long term effects; Symptoms

Indexed keywords

DUTASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; ARTICLE; BREAST CANCER; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EJACULATION DISORDER; EVALUATION; GENERAL CONDITION IMPROVEMENT; GYNECOMASTIA; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALE; OPEN STUDY; OUTCOMES RESEARCH; PATIENT CODING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SCORING SYSTEM; SYMPTOM; URINE FLOW RATE;

AGED; AZASTEROIDS; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 24044473719     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05686.x     Document Type: Article

References (19)

1. Girman CJ, Jacobsen SJ, Tsukamoto T et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428-36
2. McNicholas TA. Lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the current practice patterns? Eur Urol 2001; 39 (Suppl. 3): 26-30
3. Boyle P, Robertson C, Mazzetti C. Contacts with primary health services increase with severity of lower urinary tract symptoms (LUTS): The UrEpik study. Eur Urol 2000; 37 (Suppl 2): 1-75
4. Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277-84
5. Porru D, Bartletti R, Austoni E, Carrino M, Gianneo E, Melloni D. Relationship of flow rate with symptoms, quality of life and other clinical parameters in patients with LUTS suggestive of BPH. Eur Urol 2001; 40: 23-7
6. Girman CJ, Epstein RS, Jacobsen SJ et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825-31
7. Roberts RO, Rhodes T, Panser LA et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology 1994; 43: 621-8
8. Sells H, Donovan J, Ewings P, MacDonagh RP. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000; 85: 440-5
9. Boyle P, Robertson C, Mazzetta C, Lee C. The impact of urinary symptoms on the quality of life of the spouse: The UrEpik study. Abstract presented at the XVth Congress of the European Association of Urology, Geneva, Switzerland, April 2001
10. Tubaro A, Montanari E. Management of symptomatic BPH in Italy: who is treated and how? Eur Urol 1999; 36 (Suppl. 3): 28-32
11. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-9
12. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160: 12-7
13. Xia Z, Roberts RO, Schottenfeld D, Lieber MM, Jacobsen SJ. Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980-94. Urology 1999; 53: 1154-9
14. American Urological Association Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530-47
15. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98
16. McConnell JD, Bruskewitz R, Walsh PC et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63
17. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41
18. Debruyne F, Barkin J, van Erps P et al. Efficacy and safety of long-term treatment with the dual 5alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-95
19. Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research, how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770-4